Vir Biotechnology to present Phase 3 ECLIPSE 1 results at AASLD’s Liver Meeting
VIR•Vir Biotechnology plans to present Phase 3 ECLIPSE 1 results on Nov. 8, 2026, at AASLD’s Liver Meeting in Denver, and expanded Phase 2 SOLSTICE data on Nov. 7-8.
1. Presentations and call
The ECLIPSE 1 presentation, evaluating elebsiran with tobevibart for chronic hepatitis delta, is scheduled for 2:15 to 2:30 p.m. MT on Nov. 8. Vir Biotechnology also scheduled an investor call covering both trials for Nov. 9 at 8:30 a.m. ET / 5:30 a.m. PT; the meeting runs Nov. 5-9.
